DiagnoCure Licenses Colorectal Cancer ASRs From TDT | GenomeWeb
NEW YORK (GenomeWeb News) — DiagnoCure said yesterday that it plans to develop and sell two molecular diagnostic tests for cancer that it licensed from Targeted Diagnostics and Therapeutics.
DiagnoCure said the tests are designed to detect guanylyl cyclase C, or GCC. The company said the GCC gene appears normally in cells lining the intestines, but has only been found outside the intestine when colorectal cancer has metastasized.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.